PMS23 Cost Effectiveness Analysis of Certolizumab in Combination with Methotrexate in Patients with Moderate to Severe Rheumatoid Arthritis in Saudi Arabia

Journal article

Open access

Peer reviewed

Value in health, Vol.23, pp.S596-S596

12/2020

Files and links (1)

url

https://doi.org/10.1016/j.jval.2020.08.1154View

Published (Version of record) Open

1 Record Views

Title: PMS23 Cost Effectiveness Analysis of Certolizumab in Combination with Methotrexate in Patients with Moderate to Severe Rheumatoid Arthritis in Saudi Arabia
Creators - without role: A. Alghamdi - King Saud University
A. Alothaim - King Saud University
H. Almalaq - King Saud University
B. Balkhi - King Saud University
N. Alshehri - Riyadh Armed Forces Hospital
Publication Details: Value in health, Vol.23, pp.S596-S596
Publisher: Elsevier Inc
Identifiers: 9951837108331
Academic Unit: King Saud University
Language: English
Resource Type: Journal article